tiprankstipranks
Advertisement
Advertisement

IM Cannabis Corp. Posts Q1 2026 Results, Cuts Expenses Amid Ongoing Losses

Story Highlights
  • IM Cannabis Corp. runs a data-driven medical cannabis platform serving patients in Israel and Germany.
  • For Q1 2026, IM Cannabis reported $8.7 million revenue, a net loss, and lower operating expenses.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
IM Cannabis Corp. Posts Q1 2026 Results, Cuts Expenses Amid Ongoing Losses

Claim 55% Off TipRanks

IM Cannabis Corp ( (IMCC) ) has provided an announcement.

IM Cannabis Corp., a medical cannabis producer and distributor active in Israel and Germany, focuses on serving prescription patients via import, distribution, and retail pharmacy and online channels, supported by data-driven patient insights. In Germany, the company supplies medical cannabis to pharmacies through its Adjupharm GmbH unit.

On May 13, 2026, IM Cannabis reported first-quarter 2026 results, posting revenue of $8.7 million, gross profit of $1.4 million, an operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share. The company highlighted a 22% year-over-year reduction in general and administrative expenses and emphasized ongoing cost optimization, liquidity management supported by recent convertible note financings, and continued pursuit of strategic opportunities to support long-term growth.

Spark’s Take on IMCC Stock

According to Spark, TipRanks’ AI Analyst, IMCC is a Neutral.

The score is pressured primarily by weak profitability and a stressed balance sheet (negative equity), which outweigh the 2025 cash-flow improvement. Technically, the stock remains in a strong downtrend below key moving averages, with only oversold signals suggesting a potential (but unconfirmed) stabilization. Valuation is difficult to support due to negative earnings and no dividend information.

To see Spark’s full report on IMCC stock, click here.

More about IM Cannabis Corp

IM Cannabis Corp. is an international medical cannabis company operating primarily in Israel and Germany. It runs an integrated platform that imports and distributes cannabis to medical patients, operates retail pharmacies and online channels in Israel, and distributes medical cannabis to pharmacies in Germany through its Adjupharm GmbH subsidiary.

Average Trading Volume: 539,726

Technical Sentiment Signal: Sell

Current Market Cap: $1.57M

For a thorough assessment of IMCC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1